ResearchRSSToday
A study in Japan found that Hemlibra, a medicine used to treat acquired hemophilia A (a rare bleeding disorder that develops later in life), appears to be safe when used alongside other medications that suppress the immune system. Acquired hemophilia A is different from the hemophilia people are born with—it happens when the body mistakenly attacks its own clotting proteins. This is the first real-world evidence supporting Hemlibra's safety for this condition in actual patients.
WHY IT MATTERSIf you have acquired hemophilia A in Japan or are considering treatment options, this study suggests Hemlibra may be a safe addition to your treatment plan, though you should discuss this with your hematologist to see if it's right for your specific situation.
Clinical trialRSSMay 8
A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.
WHY IT MATTERSIf denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
AdvocacyRSSApr 22
A patient with MS shares their personal experience of why starting treatment quickly with the most powerful available medications is worth it to them. They believe the benefits of aggressive, early treatment outweigh the potential side effects. This is one patient's perspective on MS treatment strategy.
WHY IT MATTERSThis patient perspective highlights the real-world decision-making that people with MS face when choosing between starting strong treatments early versus waiting, which can help other newly diagnosed patients think through their own treatment conversations.
Clinical trialRSSApr 22
Scientists are testing a new vaccine against Epstein-Barr virus (EBV), a common virus that may trigger multiple sclerosis (MS). Early research suggests that preventing EBV infection could help prevent or reduce MS development. This vaccine could be a major breakthrough for people at risk of developing MS or those already living with the disease.
WHY IT MATTERSIf successful, an EBV vaccine could prevent MS from developing in the first place, offering a potential cure-like approach rather than just managing symptoms after diagnosis.
NewsUNITERAREApr 3
The PAN Foundation's Multiple Sclerosis Fund, which helped patients pay for MS medications and treatments, is currently closed and not accepting new applications. The fund previously offered up to $12,000 per year in financial assistance. The status changed on April 2, 2026, so it may reopen in the future.
WHY IT MATTERSIf you have MS and were relying on this fund to help pay for your medications, you'll need to find alternative financial assistance programs immediately since this specific fund is no longer accepting applications.